Dr. Bowes Rickman is a translational scientist whose research efforts over two decades have been focused on the molecular/cell biology and pathobiology of age-related macular degeneration (AMD). She holds the George and Geneva Boguslavsky Endowed Vision Research Chair, which helps support her research program. In an effort to better understand the pathophysiology of AMD, she has created a number of murine models that recapitulate many aspects of human AMD and point the way toward eventual treatments for AMD.
Philip J. Rosenfeld MD, PhD is Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. He is a retina specialist with an expertise in age-related macular degeneration (AMD), and his major contributions have included the development of anti-VEGF therapies for wet AMD and the development of clinical optical coherence tomography (OCT) instruments. Of note, he pioneered the use of Avastin (bevacizumab) therapy for exudative eye diseases, and he pioneered the use of OCT-guided therapy using anti-VEGF drugs.
Dr. Carol Shields completed her ophthalmology training at Wills Eye Hospital in Philadelphia and fellowship training in ocular oncology and ophthalmic pathology. She is Director of the Oncology Service, Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, PA USA.
Each year the Oncology Service manages over 500 patients with uveal melanoma or retinoblastoma, and hundreds of other intraocular, orbital, and conjunctival tumors from the United States and abroad. She and her husband are the proud parents of 7 children, ranging in age from 22 to 34 years.